Survo 12mg
US$65.00
Survodutide (also known as BI 456906) is a dual agonist, meaning it activates both the glucagon and GLP-1 receptors, which play a role in controlling metabolic functions. It is being developed as a potential treatment for obesity and its related complications, including metabolic dysfunction-associated steatohepatitis (MASH), and is in Phase III clinical trials.